Semaglutide vs Tirzepatide: Which GLP-1 Costs Less and Works Better?

Semaglutide and tirzepatide are the two molecules that define modern weight-management prescribing, and the honest answer to "which is better" is: it depends on whether you are optimizing for the scale or for your budget. This guide separates the efficacy evidence from the price data so you can make the trade deliberately.

Efficacy: tirzepatide leads on average

The trial evidence is unusually clean here. Semaglutide 2.4 mg (the dose used in Wegovy) produced roughly 15% mean weight loss over 68 weeks in its pivotal trial¹. Tirzepatide produced up to about 21% over 72 weeks at its highest dose in its own pivotal trial². And in a head-to-head trial in people with type 2 diabetes, tirzepatide reduced body weight and blood sugar more than a 1 mg dose of semaglutide³. That diabetes-trial comparison used a capped semaglutide dose, though — the more direct answer for weight management came later, from SURMOUNT-5, a randomized head-to-head trial in adults with obesity that compared tirzepatide directly against semaglutide 2.4 mg (Wegovy's own labeled dose) and found tirzepatide produced significantly greater weight loss, with broadly comparable safety and tolerability between the two⁴. Taken together, the data point one direction on average efficacy: tirzepatide tends to deliver more weight loss, now confirmed in a genuine apples-to-apples comparison rather than inferred across separate trials. That does not mean it is right for everyone — individual response, tolerability, and side-effect profiles vary; see tirzepatide side effects and semaglutide side effects for what the trials report, and confirm your provider follows the labeled titration schedule for whichever molecule you choose. If it's the specific brand products you're weighing rather than the molecules generally, Zepbound vs Wegovy covers approved uses and brand pricing side by side, and Saxenda vs Wegovy covers how semaglutide compares against the older liraglutide standard it displaced.

Cost: semaglutide is usually the cheaper molecule

Now flip to price. Across the compounded providers we track, semaglutide is frequently the lower-cost molecule of the two. Disclosed prices reach as low as roughly $65–$100 per month for compounded semaglutide, while compounded tirzepatide typically sits higher — often $110 to $349 per month depending on the provider and dose (per each provider's published pricing, last reviewed 2026). A handful of providers price both molecules identically, such as Found, which lists the same figure for each, and Curex; others, like Vitara RX, keep both low. Where a provider publishes its whole ladder you can price the molecule step to the dollar: Trellis Vitality's published 1/3/6-month table puts semaglutide at $150 and tirzepatide at $199 month-to-month, so the upgrade costs $49 a month, or $588 a year. You can compare live numbers in the cost calculators, or jump straight to the full tirzepatide-only annual ranking if that's the molecule you're pricing.

The value question: dollars per point of weight loss

This is where WeighLab's angle earns its keep. Tirzepatide may deliver more weight loss, but if it costs meaningfully more per month, the better value depends on how you weight results against spend. If tirzepatide costs 50% more but delivers roughly a third more average weight loss, a results-first shopper may still find it the better buy; a budget-first shopper may get most of the benefit from semaglutide at a lower sustainable cost. The wrong move is to pick the molecule on efficacy alone and then discover the price is not sustainable for a year — because a medication you stop paying for stops working.

How to decide

Start with your constraint. If cost is the hard limit, price out compounded semaglutide from a verified provider and confirm you can afford it for 12 months. If results are the priority and the budget stretches, tirzepatide's efficacy edge is real and well-evidenced. Either way, rank your finalists on total annual cost — not the intro sticker — using the true monthly cost of GLP-1, read the full provider review index, and settle it side by side on the compare tool. If needles are the deciding factor rather than price, oral semaglutide covers what's actually FDA-approved in pill form today. If you're already on one molecule and considering the other rather than choosing fresh, switching from semaglutide to tirzepatide covers the dosing and evidence questions that come with an active switch specifically, and if it's really Ozempic and Wegovy you're comparing rather than the molecules generally, Ozempic vs Wegovy untangles why the same molecule carries two different price and coverage stories. The head-to-head trial evidence is indexed in our research library.